Chronic antibody-mediated rejection
PDF (Español)
XML-JATS (Español)


Kidney transplant
Chronic graft dysfunction
chronic antibody-mediated rejection
acute kidney injury

How to Cite

Pinto Ramírez J, Celis Conde S, Camargo Salamanca A, Garcia Lopez A, Girón Luque F. Chronic antibody-mediated rejection. Rev. Colomb. Nefrol. [Internet]. 2022 Sep. 3 [cited 2024 Jul. 16];9(2). Available from:


Context: Chronic antibody-mediated rejection (cABMR) is considered one of the main causes of chronic graft.

Objective: To review the mechanisms that cause cABMR to design effective treatments, since it is very little what has been advanced in it treatment of this pathology.

Methodology: In this narrative review of the literature, we present the risk factors related to the chronic dysfunction of the injection, emphasizing the pathophysiology the diagnosis and treatment of cABMR.

Results: The most relevant risk factor for the development of chronic graft dysfunction is the development of specific donor antibodies (DSA) and ABMR. For the diagnosis of active cABMR, the criteria of Banff 2017 are required (three must be present: histological evidence of chronic tissue injury, evidence of current inflammation in the vascular endothelium caused by antibodies and serological evidence of DSA. The cABMR does not have an effective treatment.

Conclusions: Since cABMR does not have an effective treatment, it is important reduce exposure to risk factors and carry out a diagnosis and treatment of the acute events of kidney injury that contribute to the progression of chronic injection dysfunction.
PDF (Español)
XML-JATS (Español)


Saran R, Robinson B, Abbott K, Agodoa LYC, Bhave N, Bragg-Gresham J. US Renal Data System 2017 Annual Data Report. Chapter 5: Mortality. Am J Kidney Dis. 2017;71(3):S337-50.

Rosselli D, Rueda JD, Diaz C. Cost-effectiveness of kidney transplantation compared with chronic dialysis in end-stage renal disease. Saudi J Kidney Dis Transplant. 2015;26(4):733.

Axelrod DA, Schnitzler MA, Xiao H, Irish W, Tuttle-Newhall E, Chang SH, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018;18(5):1168-76.

Saran R, Robinson B, Abbott K, Al E. US Renal Data System 2017 Annual Data Report. Chapter 6: Transplantation. Am J Kidney Dis. 2017;71(3):S351-82.

El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-35.

Pascual J, Alonso Á, Burgos D, Cruzado J, Serón D. Disfunción renal crónica en pacientes trasplantados renales. Rev Nefrol. 2012;32(2):1-28.

Pinto J, Celis S, Camargo A, García A, Girón F. Moiras en trasplante renal. En: XXI Simposio Nacional de Nefrología. Valledupar, Colombia; 2019.

Loupy A, Vernerey D, Tinel C, Aubert O, Duong-van Huyen JP, Rabant M, et al. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol. 2015;26(7):1721-31.

Sellarés J, de Freitas D, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence. Am J Transplant. 2012;12:388-99.

Stegall MD, Gaston RS, Cosio FG, Matas A. Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure. J Am Soc Nephrol. 2015;26(1):20-9.

McCaughan JA, Tinckam KJ. Donor specific HLA antibodies & allograft injury: mechanisms, methods of detection, manifestations and management. Transpl Int. 2018;31:1059-70.

Zhang X, Reinsmoen NL. Impact of non-human leukocyte antigen-specific antibodies in kidney and heart transplantation. Front Immunol. 2017;8(abr.):1-7.

Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant. 2008;8(2):324-31.

Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Study report. Hum Immunol. 2009;70(8):569-73.

Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9(11):2532-41.

Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157-67.

Lan JH, Tinckam K. Clinical Utility of Complement Dependent Assays in Kidney Transplantation. Transplantation. 2018;102(1S supl. 1):S14-22.

Valenzuela NM, Schaub S. The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation. Transplantation. 2018;102(1):S7-13.

Muro M, Martorell J. Técnicas de detección de anticuerpos. En: Monitorización inmunológica del trasplante. 2015. p. 10-21.

Abbas AK, Lichtman A, Pillai S. Innate Immunity. En: Cellular and Molecular Immunology. 2017. p. 57-96.

Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12(3):574-82.

Thomas KA, Valenzuela NM, Reed EF, Angeles L. The Perfect Storm: HLA Antibodies, Complement, Fc?Rs and Endothelium in Transplant Rejection. Trends Mol Med. 2015;21(5):319-29.

Hirohashi T, Chase CM, Della-Pelle P, Sebastian D, Alessandrini A, Madsen JC, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012;12(2):313-21.

Zhang ZX, Huang X, Jiang J, Lau A, Yin Z, Liu W, et al. Natural Killer Cells Mediate Long-term Kidney Allograft Injury. Transplantation. 2015;99(5):916-24.

Zhao Y, Chen S, Lan P, Wu C, Dou Y, Xiao X, et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model. Am J Transplant. 2018;18(3):604-16.

Cross AR, Glotz D, Mooney N. The role of the endothelium during Antibody-mediated rejection: From victim to accomplice. Front Immunol. 2018;9(en.):1-7.

Valenzuela NM, Hong L, Shen X, Gao F, Young SH, Rozengurt E, et al. Blockade of P-selectin is sufficient to reduce MHC i antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant. 2013;13(2):299-311.

Naemi FM, Carter V, Kirby JA, Ali S. Anti-donor HLA class i antibodies: Pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation. 2013;96(3):258-66.

Lion J, Taflin C, Cross AR, Robledo-Sarmiento M, Mariotto E, Savenay A, et al. HLA Class II Antibody Activation of Endothelial Cells Promotes Th17 and Disrupts Regulatory T Lymphocyte Expansion. Am J Transplant. 2016;16(5):1408-20.

Béland S, Vallin P, Désy O, Lévesque E, De Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. J Thromb Haemost. 2017;15(5):1020-31.

Phillips S, Kapp M, Crowe D, Garces J, Fogo AB, Giannico GA. Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants. Hum Pathol. 2016;51:86-95.

Haas M. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts. Am J Transplant. 2018;00:1-8.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, et al. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation. 2014;97(4):440-5.

Zeng Q, Ng YH, Singh T, Jiang K, Sheriff KA, Ippolito R, et al. B cells mediate chronic allograft rejection independently of antibody production. J Clin Invest. 2014;124(3):1052-6.

Shiu KY, McLaughlin L, Rebollo-Mesa I, Zhao J, Burton H, Douthwaite H, et al. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-? production by Th1 cells. Kidney Int. 2017;91(2):477-92.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307.

Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant. 2010;10(9):2066-73.

Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, et al. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. Am J Transplant. 2018;18(2):377-90.

Akalin E. A Molecular Approach to Chronic T-cell Mediated Rejection. Transplantation. 2018;S271.

Curci C, Sallustio F, Serino G, De Palma G, Trpevski M, Fiorentino M, et al. Potential role of effector memory T cells in chronic T cell-mediated kidney graft rejection. Nephrol Dial Transplant. 2016;31(12):2131-42.

Benichou G, Gonzalez B, Marino J, Ayasoufi K, Valujskikh A. Role of memory T cells in allograft rejection and tolerance. Front Immunol. 2017;8(febr.):1-9.

Vanhove T, Goldschmeding R, Kuypers D. Kidney Fibrosis: Origins and Interventions. Transplantation. 2017;101(4):713-26.

Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med. 2018;(April):0-1.

Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, et al. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int. 2017;92(3):729-42.

Boor P, Floege J. Renal allograft fibrosis: Biology and therapeutic targets. Am J Transplant. 2015;15(4):863-86.

Venner JM, Famulski KS, Reeve J, Chang J, Halloran PF. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1(1):1-17.

Toki D, Zhang W, Hor KL, Liuwantara D, Alexander SI, Yi Z, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14(9):2126-36.

Gewin LS. Renal fibrosis: Primacy of the proximal tubule. Matrix Biol. 2018;68-69:248-62.

Nankivell BJ, Chapman JR, Bonovas G. Oral Cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation. 2004;77(9):1457-9.

Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation. 2000;69:SS11-3.

Ojo AO, Held PJ, Port FK. Chronic Renal Failure after Transplantation of a Nonrenal Organ. N Engl J Med. 2003;349(10):931-40.

Nankivell BJ, Borrows RJ, Fung CL. The Natural History of Chronic Allograft Nephropathy. N Engl J Med. 2003;349(24):2326-33.

Matas AJ. Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant. 2011;11(4):687-92.

Nankivell BJ, Ng CH, O’Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: Comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100(8):1723-31.

Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG. Renal Allograft Histology at 10 Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury. Am J Transplant. 2018;18(1):180-8.

Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol. 2018;15(en.):11-26.

Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation. 2009;87(12):1837-41.

Billing H, Rieger S, Süsal C, Waldherr R, Opelz G, Wühl E, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: A prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int. 2012;25(11):1165-73.

Muller YD, Ghaleb N, Rotman S, Vionnet J, Halfon M, Catana E, et al. Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation. Transpl Int. 2018;451-5.

Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018;18(4):927-35.

Piñeiro GJ, De Sousa-Amorim E, Solé M, Ríos J, Lozano M, Cofán F, et al. Rituximab, plasma exchange and immunoglobulins: An ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrol. 2018;19(1):1-9.

Pattonieri EF, Gregorini M, Viarengo G. Efficacy of extracorporeal photopheresis for the treatment of renal chronic antibody mediated rejection. Nephrol Dial Transplant. 2020;35(supl. 3):P1746.

Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2017;ASN.2017070818.

Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017;17(9):2381-9.

Kulkarni S, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V, et al. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. Am J Transplant. 2017;17(3):682-91.

Doberer K, Kläger J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA, et al. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation. 2020;(2):451-7.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.




Download data is not yet available.